ABCG2 and cancer: Since PLK1 inhibitors such as volasertib and genistein enhance the therapeutic sensitivity of paclitaxel-resistant cancer [17,27], we hypothesized that blocking PLK1 would suppress chemoresistance through the downregulation of ABC transporters.